NASDAQ:PTPI Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis $0.29 -0.02 (-5.67%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends About Petros Pharmaceuticals Stock (NASDAQ:PTPI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Petros Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.25▼$0.3250-Day Range$0.25▼$0.5052-Week Range$0.22▼$2.27Volume1.14 million shsAverage Volume838,902 shsMarket Capitalization$2.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPetros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.Read More… Petros Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks13th Percentile Overall ScorePTPI MarketRank™: Petros Pharmaceuticals scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Petros Pharmaceuticals. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Petros Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Petros Pharmaceuticals is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPetros Pharmaceuticals has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.98% of the float of Petros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPetros Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Petros Pharmaceuticals has recently decreased by 9.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPetros Pharmaceuticals does not currently pay a dividend.Dividend GrowthPetros Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.98% of the float of Petros Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPetros Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Petros Pharmaceuticals has recently decreased by 9.72%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A Search Interest5 people have searched for PTPI on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Petros Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.25% of the stock of Petros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.34% of the stock of Petros Pharmaceuticals is held by institutions.Read more about Petros Pharmaceuticals' insider trading history. Receive PTPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PTPI Stock News HeadlinesPetros Pharmaceuticals (NASDAQ:PTPI) Shares Down 5.8% - What's Next?December 14, 2024 | americanbankingnews.comPetros Pharmaceuticals Amends President’s Employment TermsOctober 21, 2024 | finance.yahoo.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.December 23, 2024 | Crypto Swap Profits (Ad)Positive App Study Outcomes Enhance Prospects for Petros Pharmaceuticals’ OTC StendraSeptember 13, 2024 | markets.businessinsider.comMaxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)August 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Petros Pharmaceuticals Amidst Promising Web App Technology and Strategic AdvancementsJuly 19, 2024 | markets.businessinsider.comPetros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC SwitchMay 29, 2024 | finance.yahoo.comPetros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRAMay 21, 2024 | finance.yahoo.comSee More Headlines PTPI Stock Analysis - Frequently Asked Questions How have PTPI shares performed this year? Petros Pharmaceuticals' stock was trading at $1.41 at the start of the year. Since then, PTPI shares have decreased by 79.1% and is now trading at $0.2944. View the best growth stocks for 2024 here. When did Petros Pharmaceuticals' stock split? Petros Pharmaceuticals shares reverse split on Wednesday, November 30th 2022. The 1-10 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Petros Pharmaceuticals? Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Petros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Petros Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT), Cricut (CRCT) and JPMorgan Chase & Co. (JPM). Company Calendar Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTPI CUSIPN/A CIK1815903 Webwww.petrospharma.com Phone973-242-0005FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,160,000.00 Net MarginsN/A Pretax Margin-117.50% Return on Equity-78.22% Return on Assets-23.50% Debt Debt-to-Equity Ratio1.58 Current Ratio0.85 Quick Ratio0.74 Sales & Book Value Annual Sales$4.02 million Price / Sales0.73 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.07Miscellaneous Outstanding Shares10,015,000Free Float8,788,000Market Cap$2.95 million OptionableNot Optionable Beta1.99 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:PTPI) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.